{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"25.0","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"Objective responses had to be sustained for 3 months. The percentage of participants with sustained objective responses is reported with an exact 95% confidence interval of the true sustained objective response rate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Stratum 1 patients are those with progressive unresectable or recurrent craniopharyngiomas treated with surgery alone, who had not received radiation therapy. Treatment consisted of Peginterferon alfa-2b (Sylatron) subcutaneously weekly for 6 weeks. Treatment may repeat every 6 weeks for up to 18 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Stratum 1"},{"description":"Stratum 2 patients are those with patients with progressive or recurrent craniopharyngiomas following radiation therapy. Treatment consisted of Peginterferon alfa-2b (Sylatron) subcutaneously weekly for 6 weeks. Treatment may repeat every 6 weeks for up to 18 courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Stratum 2"}],"paramType":"NUMBER","populationDescription":"Only eligible stratum 2 patients are included in this analysis. This is a \\*secondary\\* outcome measure for stratum 1 patients and is therefore reported as a separate outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Sustained Objective Response (PR+CR) Rate Observed During the First Year of Treatment (for Stratum 2 Patients Only)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}